Nanovibronix (NASDAQ:FEED) Issues Quarterly Earnings Results

Nanovibronix (NASDAQ:FEED) announced its quarterly earnings data on Monday. The company reported ($1.98) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.24 million during the quarter. Nanovibronix had a negative return on equity of 54.25% and a negative net margin of 923.20%.

Nanovibronix Trading Down 7.3%

Shares of FEED opened at $0.43 on Wednesday. The stock has a market cap of $2.62 million, a P/E ratio of -0.05 and a beta of 1.39. The stock’s 50-day moving average price is $0.50 and its two-hundred day moving average price is $1.33. Nanovibronix has a 1 year low of $0.29 and a 1 year high of $17.40.

Insiders Place Their Bets

In related news, insider Christian Michael Glibert sold 210,000 shares of Nanovibronix stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $0.69, for a total transaction of $144,900.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 12.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on FEED shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nanovibronix in a research note on Tuesday, July 21st. Wall Street Zen raised shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Nanovibronix Company Profile

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.